Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Burak DEVECİ"'
Autor:
Dilşah Başkol Elik, Şafak Kaya, Sevil Alkan, Tuna Demirdal, Alper Sener, Selçuk Kaya, Özlem Güzel Tunçcan, Bircan Kayaaslan, Rahmet Güner, Fatma Eser, Hasip Kahraman, Serhat Birengel, Elif Mukime Sarıcaoğlu, Esma Eroğlu, Fatma Çölkesen, Erman Öztürk, Hande Berk Cam, Çiğdem Mermutluoğlu, Şafak Özer Balin, Gülden Sincan, Nilgün Altın, Uluhan Sili, Bedia Mutay Suntur, Tuğba Arslan Gülen, Burak Deveci, Rabin Saba, Şaban İncecik, Gülden Eser Karlıdağ, Elif Hakko, Damla Akdağ, Hüseyin Aytaç Erdem, Hilal Sipahi, Candan Çicek, Mehmet Sezai Taşbakan, Meltem Taşbakan, Hüsnü Pullukçu, Tansu Yamazhan, Bilgin Arda, Sercan Ulusoy, Oguz Resat Sipahi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract This multicentre (22 centres in Turkey) retrospective cohort study aimed to assess the clinical outcomes of patients with neutropenic fever and SARS-CoV-2 positivity. Study period was 15 March 2020–15 August 2021. A total of 170 cases (58
Externí odkaz:
https://doaj.org/article/78519889e2af4f3b8f91d2ad66134177
Autor:
Mehmet Hilmi Dogu, Ali Irfan Emre Tekgunduz, Burak Deveci, Gulten Korkmaz, Melda Comert, Ömür Gökmen Sevindik, Osman Yokus, Istemi Serin
Publikováno v:
HemaSphere, Vol 7, p e4210211 (2023)
Externí odkaz:
https://doaj.org/article/ee805a8f01364a2b99e3ea94f643282c
Autor:
Mehmet Hilmi DOGU, Ali Irfan Emre TEKGUNDUZ, Burak DEVECI, Gulten KORKMAZ, Melda COMERT, Omur Gokmen SEVINDIK, Osman YOKUS, Istemi SERIN
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 15, Iss 1 (2023)
Background: Gilteritinib (XOSPATA ®, Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ADMIRAL trial, gilteritinib was compared with the
Externí odkaz:
https://doaj.org/article/9f3497f7aa1a4fe6aa659432d98cdc66
Autor:
Anıl Tombak, Funda Pepedil Tanrıkulu, Salih Sertaç Durusoy, Hüseyin Derya Dinçyürek, Emin Kaya, Elif Gülsüm Ümit, İrfan Yavaşoğlu, Özgür Mehtap, Burak Deveci, Mehmet Ali Özcan, Hatice Terzi, Müfide Okay, Nilgün Sayınalp, Mehmet Yılmaz, Vahap Okan, Alperen Kızıklı, Ömer Özcan, Güven Çetin, Sinan Demircioğlu, İsmet Aydoğdu, Güray Saydam, Eren Arslan Davulcu, Gül İlhan, Mehmet Ali Uçar, Gülsüm Özet, Seval Akpınar, Burhan Turgut, İlhami Berber, Erdal Kurtoğlu, Mehmet Sönmez, Derya Selim Batur, Rahşan Yıldırım, Vildan Özkocaman, Ahmet Kürşad Güneş, Birsen Sahip, Şehmus Ertop, Olga Meltem Akay, Abdülkadir Baştürk, Mehmet Hilmi Doğu, Aydan Akdeniz, Ali Ünal, Ahmet Seyhanlı, Emel Gürkan, Demet Çekdemir, Burhan Ferhanoğlu
Publikováno v:
Turkish Journal of Hematology, Vol 38, Iss 4, Pp 273-285 (2021)
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +- standard deviat
Externí odkaz:
https://doaj.org/article/506b9a34c2d64dd5beb096f766347808
Autor:
Fergün Yılmaz, Nur Soyer, Güldane Cengiz Seval, Sinem Civriz Bozdağ, Pervin Topcuoğlu, Ali Ünal, Leylagül Kaynar, Gökhan Özgür, Gülsan Türköz Sucak, Hakan Göker, Mustafa Velet, Hakan Özdoğu, Mehmet Yılmaz, Emin Kaya, Ozan Salim, Burak Deveci, İhsan Karadoğan, Güray Saydam, Fahri Şahin, Filiz Vural
Publikováno v:
Turkish Journal of Hematology, Vol 38, Iss 3, Pp 195-203 (2021)
Objective: Although inhibition of the complement system at different steps is a promising therapy modality in patients with paroxysmal nocturnal hemoglobinuria (PNH), allogeneic hematopoietic stem cell transplantation (HCT) is still the only curative
Externí odkaz:
https://doaj.org/article/5bce8903a2b2414e88326fb73088f77a
Publikováno v:
Turkish Journal of Hematology, Vol 29, Iss 1, Pp 94-95 (2012)
Externí odkaz:
https://doaj.org/article/aa67a62cce6f4f89b7c89ed804698b51
Autor:
Muzaffer Keklik, Burak Deveci, Serhat Celik, Kemal Deniz, Zeynep Burcin Gonen, Gokmen Zararsiz, Rabin Saba, Gulsah Akyol, Yusuf Ozkul, Leylagul Kaynar, Ertugrul Keklik, Ali Unal, Mustafa Cetin, Olcay Y. Jones
Publikováno v:
Annals of Hematology. 102:1537-1547
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4341cb65bd908555f4e9266b4eb0ce31
https://doi.org/10.1007/s00277-023-05216-3
https://doi.org/10.1007/s00277-023-05216-3
Autor:
Burak Deveci
Publikováno v:
Türk Dili ve Edebiyatı Dergisi / Journal of Turkish Language and Literature. 62:325-352
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed35279b28a9f0417532656f11f1bddd
https://doi.org/10.26650/tuded2022-1119114
https://doi.org/10.26650/tuded2022-1119114
Autor:
Elif Birtas Atesoglu, Zafer Gulbas, Ant Uzay, Muhit Ozcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Fergun Yilmaz, Derya Koyun, Nihan Alkis, Inci Alacacioglu, Mehmet Sonmez, Irfan Yavasoglu, Anil Tombak, Ozgur Mehtap, Fatih Kurnaz, Orhan Kemal Yuce, Volkan Karakus, Mehmet Turgut, Derya Deniz Kurekci, Mesut Ayer, Muzaffer Keklik, Deram Buyuktas, Murat Ozbalak, Burhan Ferhanoglu
Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2497f4e81be510fd6626ab724fb52159
https://hdl.handle.net/11424/289907
https://hdl.handle.net/11424/289907
Autor:
Ozlem Alhan, Rabin Saba, Emin Halis Akalin, Beyza Ener, Zeynep Ture Yuce, Burak Deveci, Mehmet Mucahit Guncu, Huseyin Nadir Kahveci, Asu Fergun Yilmaz, Zekaver Odabasi
Background: A rapid and reliable diagnostic test is needed to reduce mortality through early diagnosis of invasive aspergillosis (IA) in patients with hematological malignancies. Objective: To evaluate the efficacy of serum and bronchoalveolar lavage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a8e630e3f53a764db16de1ca31cb60
https://doi.org/10.21203/rs.3.rs-2782725/v1
https://doi.org/10.21203/rs.3.rs-2782725/v1